Antiplatelet therapy: Eptifibatide is noninferior to abciximab: Implications for clinical practice

Nature Reviews Cardiology

Volumn 7, Issue 10, 2010, Pages 539-

  King, Alexandra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 77957315738     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.128     Document Type: Article

References (2)

1. Zeymer, U. et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMITrial. J. Am. Coll. Cardiol. 56, 463-469 (2010)
2. Åkerblom, A. et al. Eptifibatide is noninferiorto abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry), J. Am. Coll. Cardiol. 56, 470-475 (2010)